MX2018007772A - Terapia de combinacion. - Google Patents
Terapia de combinacion.Info
- Publication number
- MX2018007772A MX2018007772A MX2018007772A MX2018007772A MX2018007772A MX 2018007772 A MX2018007772 A MX 2018007772A MX 2018007772 A MX2018007772 A MX 2018007772A MX 2018007772 A MX2018007772 A MX 2018007772A MX 2018007772 A MX2018007772 A MX 2018007772A
- Authority
- MX
- Mexico
- Prior art keywords
- alaninyl
- benzoxy
- combination therapy
- phenyl
- phosphate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención se refiere a una combinación de gemcitabina-[fenil-benzoxi-L-alaninil)]-fosfato (nombre químico: 2´-deoxi-2´,2´-difluoro-D-citidina-5´-O-[fenil (benzoxi-L-alaninil)]). (NUC-1031) y un agente anticancerígeno a base de platino seleccionado de cisplatino, picoplatino, lipoplatino y triplatino; las combinaciones son útiles en el tratamiento de cáncer y particularmente del cáncer del conducto biliar y cáncer de vejiga.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2015/054158 WO2017109444A1 (en) | 2015-12-23 | 2015-12-23 | Combination therapy |
GBGB1609770.1A GB201609770D0 (en) | 2016-06-03 | 2016-06-03 | Combination therapy |
PCT/GB2016/054018 WO2017109486A1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007772A true MX2018007772A (es) | 2019-07-04 |
Family
ID=57681677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007772A MX2018007772A (es) | 2015-12-23 | 2016-12-21 | Terapia de combinacion. |
Country Status (29)
Country | Link |
---|---|
US (2) | US20190022117A1 (es) |
EP (2) | EP3738595A1 (es) |
JP (1) | JP6898329B2 (es) |
KR (1) | KR20180096698A (es) |
CN (1) | CN108697725A (es) |
AU (1) | AU2016375861B2 (es) |
CA (1) | CA3008749C (es) |
CY (1) | CY1122835T1 (es) |
DK (1) | DK3393478T3 (es) |
EA (1) | EA037459B1 (es) |
ES (1) | ES2778933T3 (es) |
HK (1) | HK1255110A1 (es) |
HR (1) | HRP20200423T1 (es) |
HU (1) | HUE050290T2 (es) |
IL (1) | IL260076A (es) |
LT (1) | LT3393478T (es) |
MA (1) | MA51576A (es) |
MD (1) | MD3393478T2 (es) |
ME (1) | ME03677B (es) |
MX (1) | MX2018007772A (es) |
MY (1) | MY194629A (es) |
PH (1) | PH12018501339A1 (es) |
PL (1) | PL3393478T3 (es) |
PT (1) | PT3393478T (es) |
RS (1) | RS60211B1 (es) |
SG (1) | SG11201805184TA (es) |
SI (1) | SI3393478T1 (es) |
WO (1) | WO2017109486A1 (es) |
ZA (1) | ZA201804155B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY176133A (en) | 2012-11-16 | 2020-07-24 | Nucana Biomed Ltd | Process for preparing nucleoside prodrugs |
AU2015278900B2 (en) | 2014-06-25 | 2019-04-04 | NuCana plc | Formulation comprising a gemcitabine-prodrug |
TWI695718B (zh) | 2014-06-25 | 2020-06-11 | 英商努卡那公眾有限公司 | 前藥 |
GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
JP7038653B2 (ja) | 2015-10-05 | 2022-03-18 | ニューカナ パブリック リミテッド カンパニー | 併用療法 |
AU2016367237B2 (en) | 2015-12-11 | 2020-12-24 | Laurus Labs Limited | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031 |
GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
CN104271117A (zh) * | 2012-08-13 | 2015-01-07 | 雷格伦公司 | 利用Lipoplatin治疗癌症的方法 |
EP2919790B1 (en) * | 2012-11-13 | 2018-04-04 | Boyen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
EP3415149A1 (en) * | 2015-05-14 | 2018-12-19 | NuCana plc | Cancer treatments |
JP7038653B2 (ja) * | 2015-10-05 | 2022-03-18 | ニューカナ パブリック リミテッド カンパニー | 併用療法 |
-
2016
- 2016-12-21 MX MX2018007772A patent/MX2018007772A/es unknown
- 2016-12-21 MY MYPI2018001015A patent/MY194629A/en unknown
- 2016-12-21 EP EP20160070.7A patent/EP3738595A1/en not_active Withdrawn
- 2016-12-21 EA EA201891473A patent/EA037459B1/ru unknown
- 2016-12-21 PT PT168200053T patent/PT3393478T/pt unknown
- 2016-12-21 SI SI201630680T patent/SI3393478T1/sl unknown
- 2016-12-21 KR KR1020187020533A patent/KR20180096698A/ko not_active Application Discontinuation
- 2016-12-21 JP JP2018532746A patent/JP6898329B2/ja active Active
- 2016-12-21 RS RS20200297A patent/RS60211B1/sr unknown
- 2016-12-21 CA CA3008749A patent/CA3008749C/en active Active
- 2016-12-21 MD MDE20181039T patent/MD3393478T2/ro unknown
- 2016-12-21 AU AU2016375861A patent/AU2016375861B2/en active Active
- 2016-12-21 DK DK16820005.3T patent/DK3393478T3/da active
- 2016-12-21 EP EP16820005.3A patent/EP3393478B1/en active Active
- 2016-12-21 SG SG11201805184TA patent/SG11201805184TA/en unknown
- 2016-12-21 CN CN201680082464.9A patent/CN108697725A/zh active Pending
- 2016-12-21 MA MA051576A patent/MA51576A/fr unknown
- 2016-12-21 HU HUE16820005A patent/HUE050290T2/hu unknown
- 2016-12-21 PL PL16820005T patent/PL3393478T3/pl unknown
- 2016-12-21 WO PCT/GB2016/054018 patent/WO2017109486A1/en active Application Filing
- 2016-12-21 ME MEP-2020-56A patent/ME03677B/me unknown
- 2016-12-21 LT LTEP16820005.3T patent/LT3393478T/lt unknown
- 2016-12-21 US US16/065,498 patent/US20190022117A1/en not_active Abandoned
- 2016-12-21 ES ES16820005T patent/ES2778933T3/es active Active
-
2018
- 2018-06-17 IL IL260076A patent/IL260076A/en unknown
- 2018-06-21 ZA ZA2018/04155A patent/ZA201804155B/en unknown
- 2018-06-21 PH PH12018501339A patent/PH12018501339A1/en unknown
- 2018-11-08 HK HK18114265.9A patent/HK1255110A1/zh unknown
-
2020
- 2020-03-16 HR HRP20200423TT patent/HRP20200423T1/hr unknown
- 2020-03-17 CY CY20201100245T patent/CY1122835T1/el unknown
-
2022
- 2022-06-21 US US17/845,878 patent/US20230149436A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501339A1 (en) | Combination therapy | |
PH12018500691A1 (en) | Combination therapy | |
MA44110B1 (fr) | Polythérapie | |
MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
MX2019001920A (es) | Arn la terapia contra el cancer. | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
NZ738149A (en) | Use of exosomes for the treatment of disease | |
MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
PH12015501744B1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
NZ628021A (en) | Pharmaceutical composition comprising empagliflozin and antiobesity drug | |
SG10201906075VA (en) | Methods of treating cancer | |
MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
MY171994A (en) | Use of sigma ligands in bone cancer pain | |
CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
MA34057B1 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
PH12018502491A1 (en) | Cancer treatments | |
MX2019003694A (es) | Metodos para tratar cancer del tracto biliar. | |
MX2018006953A (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer. | |
MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
MX2019002947A (es) | Combinaciones que incluyen abx196 para el tratamiento de cancer. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2019006685A (es) | Combinacion terapeutica para el tratamiento de cancer. | |
SG11201808253YA (en) | Marker for predicting treatment response to anti-cancer agent in solid cancer patients |